Increasing evidence suggests that
inflammation contributes to the etiology and progression of
schizophrenia. Molecules that initiate
inflammation, such as virus- and toxin-induced
cytokines, are implicated in neuronal degeneration and
schizophrenia-like behavior. Using therapeutic agents with anti-inflammatory or neurotrophic effects may be beneficial for treating
schizophrenia. One hundred healthy controls and 95 Han Chinese patients with
schizophrenia were tested in this double-blind study. Their PANSS scores, plasma
interleukin (IL)-1β,
tumor necrosis factor-α (TNF-α) and
brain-derived neurotrophic factor (
BDNF) levels were measured before and after pharmacological treatment. Pretreatment, plasma levels of IL-1β and TNF-α were significantly higher in patients with
schizophrenia than in controls, but plasma
BDNF levels were significantly lower. Patients were treated with the atypical
antipsychotic risperidone (Risp) only or with Risp+
dextromethorphan (DM). PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and
BDNF levels significantly increased after 11 weeks of Risp treatment. Patients in the Risp+ DM group showed a greater and earlier reduction of symptoms than did those in the Risp-only group. Moreover, Risp+ DM treatment attenuated Risp-induced plasma increases in TNF-α. Patients with
schizophrenia had a high level of peripheral
inflammation and a low level of peripheral
BDNF. Long-term Risp treatment attenuated
inflammation and potentiated the neurotrophic function but also produced a certain degree of toxicity. Risp+ DM was more beneficial and less toxic than Risp-only treatment.
CLINICAL TRIAL REGISTRATION: NCT01189006; URL: http://www.clinicaltrials.gov.